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month after of the surgery we applied EORTC questionnaires QLQ-C30, PR25, and 
IN-PATSAT32. The scores for each questionnaire were calculated according formulas 
and instruction in the EORTC Scoring Manual. We calculated mean and standard 
deviation for each score. Results: Global Health Status/QoL has a mean score 74.80 
(±20.74); the functional scales: physical 87.4 (±18.08); emotional 80.3 (±17.23); role 
87.6 (±24.44), social 89.4 (±20.09). Symptoms scales: fatigue 15.6 (±15.48); insomnia, 
27.3 (±30.00), pain 12 (±17.27), constipation 18.4 (±27.63), financial difficulties 17 
(±29.38) the others symptom scales showed mean scores under 10. For scales in PR25 
questionnaire, the scores were: sexual activity 72.7 (±20.68), sexual function 59.0 
(±31.45); urinary symptoms 32.5 (±21.57), symptoms related with hormonal therapy 
17.5 (±14.13), incontinence support 29.2 (±38.24). About scores for IN-PATSAT32, for 
doctors: Interpersonal skills 88.30 (±16.72); technical skills 87.23 (±19.95); capacity 
to bring information 89.01 (±17.29); availability 88.56 (±16.85); for nurse: interper-
sonal skills 87.41 (±16.74) technical skills 86.52 (±18.51); capacity to bring infor-
mation 84.40 (±19.00); availability 79.26 (±20.89); other personnel kindness 80.85 
(±20.47), access 76.86 (±23.16), waiting time 82.18 (±21.45), exchange of informa-
tion 77.66 (±22.86), comfort/cleanness 80.85 (±21.62) and general satisfaction 84.57 
(±18.46). ConClusions: The functional scales for QLQ-C30 showed a good quality 
of life, however symptom scales related to sexual function showed a diminished 
QoL, satisfaction with doctors and nurses is good, but not for other personnel.
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objeCtives: To determine the HRQoL scores in multiple myeloma patients who 
are receiving treatment in a tertiary referral hospital. Methods: Outpatients 
attended consecutively at the hematology department were enrolled, at any 
stage of treatment. We interviewed through EORTC questionnaires: QLQ30, MY20 
and INPATSAT32. The medians and percentiles were calculated. Questionnaire 
scores were calculated according to formulas and instructions of the EORTC scor-
ing manual. Results: 23 patients were analyzed; the median of age was 62.21 
years (interquartile interval 59.02-69.88). 69.56% were men. Global health status/
QoL showed a median score of 66.67 (P25= 62.5, P75= 83.33), emotional function-
ing 83.33 (P25= 58.33, P75= 91.66), pain scale 33.33 (P25= 16.66, P75= 50.00), insom-
nia 33.33 (P25= 0, P75= 33.33), fatigue 33.33 (P25= 16.66, P75= 44.44). The median for 
the body image scale was 100.00 (P25= 50.00, P75= 100.00) and future perspective 
was 77.78 (P25= 55.55, P75= 97.22), the other medians: symptoms 27.78 (P25= 13.88, 
P75= 38.88), treatment-related side effects 20.00 (P25= 8.33, P75= 36.66). In the sat-
isfaction questionnaire, the scores for the doctor showed: technical skills 75.00 
(P25= 54.16, P75= 97.91), information provided 41.67 (P25= 25.00, P75= 58.33) for nurs-
ing: technical skills 75.00 (P25= 58.33, P75= 89.58) and information provided 75.00 
(P25= 50.00, P75= 91.66), waiting times 62.50 (P25= 50.00, P75= 96.87) and in overall 
satisfaction average was 75.00 (P25= 50.00, P75= 93.75). ConClusions: Multiple 
myeloma patients treated in this hospital show favorable results on scores of qual-
ity of life in terms of symptoms of the disease and treatment-related side effects, 
especially in the fatigue. These results can be compared satisfactory accordingly 
with other reports from the international literature.
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objeCtives: To determine HRQoL and patient satisfaction scores in colorectal can-
cer patients treated through radical surgery with a curative intent. Methods: Were 
selected colorectal cancer patients treated through radical surgery. One month after 
of the surgery we applied EORTC questionnaires QLQ-C30, CR29, and IN-PATSAT32. 
The scores for each questionnaire were calculated according formulas and instruc-
tion in the EORTC Scoring Manual. We calculated median and percentilar values 
25 and 75 for each score. Results: Were studies 83 colorectal cancer patients: 
34 women and 49 men, the results for EORTC questionnaires are: Global Health 
Status/QoL has a median score 83.33 (70.83-100); the functional scales: physical 93.33 
(83.33-100); emotional 83.33 (75-91.67); role 100 (83.33-100), social 100 (83.33-100). 
Symptoms scales: fatigue 11.11 (0.00-33.33); insomnia, 0.00 (0.00-0.00), pain 0.00 
(0.00-16.67), constipation 0.00 (0.00-33.33), financial difficulties 0.00 (0.00-33.33). For 
scales in CR29 questionnaire, the scores were: body image 100 (83.3-100), anxiety 
66.67 (66.67-100); sexual interest in women 0.00 (0.00-33.33), sexual interest male 
33.33 (0.00-33.33), urinary frequency 16.67 (0.00-33.33), blood stool 0.00 (0.00-16.67), 
stool frequency 0.00 (0.00-16.66), urinary incontinence 0.00 (0.00-0.00). About scores 
for IN-PATSAT32, for doctors: Interpersonal skills 100 (91.66-100); technical skills 
100 (95.83-100); capacity to bring information 100 (91.66-100); availability 100 (100-
100); for nurse: interpersonal skills 100 (91.66-100) technical skills 100 (83.33-100); 
capacity to bring information 91.67 (70.83-100); availability 87.50 (75.00-100); other 
personnel kindness 91.67 (83.33-100), access 87.50 (62.5-100), waiting time 87.50 
(62.5-100), exchange of information 100 (75-100), comfort/cleanness 75.00 (75.00-100) 
and general satisfaction 75.00 (75.00-100). ConClusions: The functional scales for 
QLQ-C30 showed a good quality of life, however symptom scales related to sexual 
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objeCtives: To explore individual’s preferences concerning genetic screening for 
colorectal cancer (CRC) within a population-based CRC screening program and to 
calculate the initial uptake of genetic screening for different scenarios based on 
the three major categories of genetic CRC; familial adenomatous polyposis (FAP), 
hereditary non-polyposis colorectal cancer or Lynch syndrome and other famil-
ial non-polyposis colorectal cancer (FCC). Methods: By means of ongoing data 
collection, a Discrete Choice Experiment (DCE) questionnaire was sent to a rep-
resentative sample of the Dutch population aged 55-65years. The DCE included 
nine D-efficient designed choice tasks. Panel-mixed-logit models were used to 
estimate the relative importance of the four included genetic screening attrib-
utes; risk of being genetically predisposed, risk of developing CRC, frequency of 
follow-up colonoscopies, survival rate. The potential uptake was calculated for the 
three screening scenarios. Results: When the chance of being genetically predis-
posed increased, respondents were more likely to participate in genetic screening. 
Respondents preferred biannual and annual colonoscopies over having a follow-up 
colonoscopy every 5 years. Increasing predicted CRC survival rates were associ-
ated with increased willingness to participate in screening. The risk of developing 
CRC as a result of being genetically predisposed did not impact the willingness of 
respondents to participate in screening. The frequency of follow-up colonoscopies 
was relatively most important for respondents when deciding about participation 
in genetic screening. The calculated potential uptake rates were high with respec-
tively 91.3% for the FCC, 91.9% for the Lynch and 91.0% for the FAP screening sce-
nario. ConClusions: Individuals are willing to participate in genetic screening for 
CRC. This decision is mostly driven by the frequency of follow-up colonoscopies, CRC 
survival rate and the chance of being genetically predisposed. This interest of the 
general public in genetic screening should be taken into account when discussing 
about the possibility of introducing genetic screening in population-based cancer 
screening programs.
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objeCtives: MBC is an incurable disease for which NVBOral is a standard treat-
ment available in 45 countries. The burden of disease, treatment patterns and 
motivation to choose across treatments and their consequences are seldom 
described in the real world. Methods: A prospective observational study was 
conducted to assess the global burden of disease and treatment with NVBOral or 
ivVino in Czech Republic, France, Germany, Italy, Poland and Spain. Patients and 
disease characteristics at inclusion, events, tolerability, hospitalisations observed 
during one cycle of treatment, and reasons to choose either route of administra-
tion are described. Eligible patients received NVBOral either alone or combined 
with capecitabine, or ivVino either alone or combined with capecitabine or tras-
tuzumab. Results: 184 patients were registered in 6 European countries: 128 
with NVBOral and 56 with ivVino. Patients’ characteristics differed significantly 
only in term of age (64 years for NVBOral and 58 years for ivVino, p= .001) and 
time between diagnosis and inclusion (104 and 71 months respectively, p= .002). 
NVBOral was mainly given to patients with HER2-negative (90%), estrogen-pos-
itive (80%) and progesterone-positive (62%) disease (ivVino: 66%, 66% and 51% 
respectively). Patients in the two cohorts had similar performance status and 
were similarly distributed across chemotherapy lines. NVBOral was mainly chosen 
for patients’ convenience (93%) and upon patients’ request (21%) (ivVino: 30% 
and 12% respectively). The two treatments were similarly safe, with grade 3/4 
neutropenia in 2% with NVBOral and 6% with ivVino, nausea and vomiting in 2% 
and none respectively. NVBOral was given without interruption, delay, or dose 
adjustment in 85% of patients (ivVino: 78%). Hospitalisation was required during 
the cycle observed for 14% and 26% of patients respectively. ConClusions: In 
this European prospective observational study, NVBOral appeared a safe, patient-
convenient and easy to manage treatment for MBC patients. NVBOral is used 
particularly after hormonal therapy.
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objeCtives: To determine HRQoL and patient satisfaction scores in prostate cancer 
patients treated through radical prostatectomy with a curative intent. Methods: 
Were selected prostate cancer patients treated through radical prostatectomy. One 
